Treatment of ranula in pediatric patients with intralesional injection of OK-432.

Abstract

OBJECTIVE:

To assess the efficacy of treatment of a ranula in children by intralesional injection of OK-432.

STUDY DESIGN:

Retrospective analysis of 13 cases.

METHODS:

Review of medical records of pediatric patients with ranula treated by OK-432 sclerotherapy from 2002 through 2005.

RESULTS:

Among 13 cases, 9 were completely regressed by injection therapy alone. Three cases were incompletely regressed. One case was cured by surgical excision. The follow-up duration was 6 to 46 (mean 24.3) months. Adverse effects of OK-432 injection were tolerable, and no complication was observed.

CONCLUSIONS:

On the basis of our experience, sclerotherapy with OK-432 was a safe and effective primary treatment for a ranula in children. Further study will be needed to conclude its long-term effectiveness.

• Authors: Heung-Man Lee, Hyun-Woo Lim, Hee Joon Kang, Sung-Won Chae, Soon-Jae Hwang, Kwang-Yoon Jung, Jeong-Soo Woo
• Journal: The Laryngoscope (Laryngoscope) Vol. 116 Issue 6 Pg. 966-9 (Jun 2006) ISSN: 0023-852X [Print] United States
• PMID: 16735909 (Publication Type: Journal Article)

Chemical References

• Sclerosing Solutions
• Picibanil

Topics

• Adolescent
• Child
• Female
• Humans
• Injections, Intralesional
• Male
• Picibanil (administration & dosage)
• Ranula (drug therapy)
• Retrospective Studies
• Sclerosing Solutions (administration & dosage)
• Treatment Outcome